Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidemiologic study
Autore:
Evers, S; Gralow, I; Bauer, B; Suhr, B; Buchheister, A; Husstedt, IW; Ringelstein, EB;
Indirizzi:
Univ Munster, Dept Neurol, D-48129 Munster, Germany Univ Munster MunsterGermany D-48129 pt Neurol, D-48129 Munster, Germany Univ Munster, Dept Anesthesiol, D-48129 Munster, Germany Univ Munster Munster Germany D-48129 esthesiol, D-48129 Munster, Germany
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 4, volume: 22, anno: 1999,
pagine: 201 - 206
SICI:
0362-5664(199907/08)22:4<201:SAEOAD>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLUSTER HEADACHE; MIGRAINE; WITHDRAWAL; TARTRATE; ABUSE;
Keywords:
drug overuse; drug-induced headache; ergotamine; sumatriptan;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Evers, S Univ Munster, Dept Neurol, Albert Schweitzer Str 33, D-48129 Munster, Germany Univ Munster Albert Schweitzer Str 33 Munster Germany D-48129ny
Citazione:
S. Evers et al., "Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidemiologic study", CLIN NEUROP, 22(4), 1999, pp. 201-206

Abstract

Drug-induced headache, particularly ergotamine-induced headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine drugs such as sumatriptan can lead to overuse and subsequent drug-induced headache. We performed a controlled study to identify the rate of sumatriptan overuse and sumatriptan-induced headache andcompared it to the rate of ergotamine overuse and ergotamine-induced headache. Two thousand sixty-five consecutive headache patients, all experiencedin intake of sumatriptan (n = 631) or ergotamine (n = 620), were enrolled over a three-year study period. The rates of overuse and drug-induced headache and the clinical features of the subgroups were compared. Risk factors for sumatriptan overuse were identified. The rates of ergotamine and sumatriptan overuse were 14.2% and 3.5%, respectively (p < 0.001). Drug-induced headache could be found more frequently in cases of ergotamine overuse than incases of sumatriptan overuse (68% versus 32%; p < 0.01). Development of sumatriptan overuse was most common in patients with previous drug-induced headache (68%), combined headache as the primary headache type (45%), and subcutaneous application of sumatriptan (45%). We conclude that sumatriptan intake can lead to overuse and subsequent drug-induced headache. The risk for overuse and drug-induced headache is significantly lower than in patientswith ergotamine intake. This might be caused in part by the relatively short period of sumatriptan availability on the market. The new generation of serotonin-1B/D-receptor agonists in the treatment of headache should have apotential for overuse similar to that of traditional headache drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 01:05:01